Medigene AG: Medigene participates at further conferences in September 2018

Published: Sep 12, 2018

Medigene AG

Martinsried/Munich (pta/11.09.2018/07:30)  -- MediGene AG (FSE: MDG1, Prime Standard, TecDAX) today announced its participation at the following upcoming investor and scientific conferences:

Phacilitate Cell & Gene Therapy Europe 
Date: 11 - 12 September 2018
Location: London, UK

Baader Investment Conference 
Date: 24 - 27 September 2018
Location: Munich, Germany

Berenberg Bank and Goldman Sachs German Corporate Conference 
Date: 24 - 26 September 2018
Location: Munich, Germany

APV Interactive Workshop on ATMP - Bridging big pharma concepts and ATMP 
Date: 27 - 28 September 2018
Location: Vienna, Austria
Dr Kai Pinkernell, CMO and CDO of Medigene AG, is invited to hold a presentation on the topic "Development and commercialization aspects of cellular immunotherapies".

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

For more information, please visit http://www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01, 
email: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

(Ende)

 

Back to news